Rationale, design and organisation of an efficacy and safety study of oxypurinol added to standard therapy in patients with NYHA class III – IV congestive heart failure

Bibliography

• MASSEY V, KOMAI H, PALMER G et al: On the mechanism of inactivation of xanthine oxidase by allopurinol and other pyrazolo [3, 4-d]pyrimidines. J. Biol. Chem.(1970) 245:2837–2844.
   PubMed Web of Science ®Google Scholar
• ELION GB: The purine path to chemotherapy. Science (1989) 244:41–47.
   PubMed Web of Science ®Google Scholar
• ••Review of purine pathway by Elion, whodescribed oxypurinol.
   Google Scholar
• WALTER-SACK I, DEVRIES JX, ERNST B et al: Uric acid lowering effect of oxipurinol sodium in hyperuricemic patients - therapeutic equivalence to allopurinol. Rheumatol (1996) 23:498–501.
   Web of Science ®Google Scholar
• ANKER SD, DOEHNER W, RAUCHHAUS M et al.: Uric acid and survival in chronic heart failure: validation and application in metabolic, functional, and hemodynamic staging. Circulation (2003) 107:1991–1997.
   PubMed Web of Science ®Google Scholar
• HARE JM, JOHNSON RJ: Uric acid predicts clinical outcomes in heart failure - insights regarding the role of xanthine oxidase and uric acid in disease pathophysiology. Circulation (2003) 107:1951–1953.
   PubMed Web of Science ®Google Scholar
• BERRY CE, HARE JM: Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications. J. Physic] (2004) 555:589–606.
   Google Scholar
• ••Comprehensive review of relevantbiochemistry and enzymology.
   Google Scholar
• CESSELLI D, JAKONIUK I, BARLUCCHI L et al.: Oxidative stress-mediated cardiac cell death is a major determinant of ventricular dysfunction and failure in dog dilated cardiomyopathy. Circ. Res. (2001) 89:279–286.
   PubMed Web of Science ®Google Scholar
• SPIEKERMANN S, LANDMESSER U, DIKALOV S et al: Electron spin resonance characterization of vascular xanthine and NAD(P)H oxidase activity in patients with coronary artery disease: relation to endothelium-dependent vasodilation. Circulation (2003) 107:1383–1389.
   PubMed Web of Science ®Google Scholar
• EKELUND UEG, HARRISON RW, SHOKEK 0 et al.: Intravenous allopurinol decreases myocardial oxygen consumption and increases mechanical efficiency in dogs with pacing-induced heart failure. Circ. Res. (1999) 85:437–445.
   Google Scholar
• •Initial description that X0I improves cardiac mechanoenergetics.
   Google Scholar
• SAAVEDRA WE PAOLOCCI N, ST JOHN ME et al.: Imbalance between xanthine oxidase and nitric oxide synthase signaling pathways underlies mechanoenergetic uncoupling in the failing heart. Circ. Res. (2002) 90:297–304.
   PubMed Web of Science ®Google Scholar
• DOEHNER W, SCHOENE N, RAUCHHAUS M et al.: Effects of xanthine oxidase inhibition with allopurinol on endothelial function and peripheral blood flow in hyperuricemic patients with chronic heart failure: results from 2 placebo-controlled studies. Circulation (2002) 105:2619–2624.
   PubMed Web of Science ®Google Scholar
• LANDMESSER U, SPIEKERMANN S, DIKALOV S et al.: Vascular oxidative stress and endothelial dysfunction in patients with chronic heart failure: role of xanthine-oxidase and extracellular superoxide dismutase. Circulation (2002) 106:3073–3078.
   PubMed Web of Science ®Google Scholar
• ••Description of X0 as a cause ofcardiovascular oxidative stress.
   Google Scholar
• FARQUHARSON CA, BUTLER R, HILL A et al: Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation (2002) 106:221–226.
   PubMed Web of Science ®Google Scholar
• ADAMS V, JIANG H, YU JT et al: Apoptosis in skeletal myocytes of patients with chronic heart failure is associated with exercise intolerance. J. Am. Coll. Cardiol. (1999) 33:959–965.
   PubMed Web of Science ®Google Scholar
• PEREZ NG, GAO WD, MARBAN E: Novel myofilament Ca2'-sensitizing property of xanthine oxidase inhibitors. Circ. Res. (1998) 83:423–430.
   PubMed Web of Science ®Google Scholar
• •Seminal description that X0 contributes to myofilament stunning and depressed response to activator calcium.
   Google Scholar
• CAPPOLA TP, KASS DA, NELSON GS et al.: Allopurinol improves myocardial efficiency in patients with idiopathic dilated cardiomyopathy. Circulation (2001) 104:2407–2411.
   PubMed Web of Science ®Google Scholar
• •Seminal description that X0I restores mechanoenergetic uncoupling in human heart failure.
   Google Scholar
• MacFARLANE NG, MILLER DJ: Depression of peak force without altering calcium sensitivity by the superoxide anion in chemically skinned cardiac-muscle of rat. Circ. Res. (1992) 70:1217–1224.
   PubMed Web of Science ®Google Scholar
• GAO WD, PEREZ NG, MARBAN E: Calcium cycling and contractile activation in intact mouse cardiac muscle. ./. Physiol (1998) 507(Pt 1):175–184.
   PubMed Web of Science ®Google Scholar
• ISHIHARA H, YOKOTA M, SOBUE T et al: Relation between ventriculoarterial coupling and myocardial energetics in patients with idiopathic dilated cardiomyopathy. I Am. Coll. Cardiol. (1994) 23:406–416.
   PubMed Web of Science ®Google Scholar
• WOLFF MR, DETOMBE PP, HARASAWA Y et al.: Alterations in left-ventricular mechanics, energetics, and contractile reserve in experimental heart-failure. Circ. Res. (1992) 70:516–529.
   PubMed Web of Science ®Google Scholar
• UKAI T, CHENG CP, TACHIBANA H et al: allopurinol enhances the contractile response to dobutamine and exercise in dogs with pacing-induced heart failure. Circulation (2001) 103:750–755.
   PubMed Web of Science ®Google Scholar
• KOGLER H, FRASER H, McCUNE S et al.: disproportionate enhancement of myocardial contractility by the xanthine oxidase inhibitor oxypurinol in failing rat myocardium. Cardiovasc. Res. (2003) 59:582–592.
   PubMed Web of Science ®Google Scholar
• GRAHAM S, DAY RO, WONG H et al.:Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br. J. Clin. Pharmacol (1996) 41:299–304.
   PubMed Web of Science ®Google Scholar
• WALTER-SACK I, DE VRIES JX, KUTSCHKER C et al.: Disposition and (2004)13(11) uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur. I Clia Pharmacol (1995) 49:215–220.
   PubMed Web of Science ®Google Scholar
• EARLL JM, SAAVEDRA M: Oxipurinoltherapy in allopurinol-allergic patients. Am. Fam. Physician. (1983) 28:147–148.
   PubMed Web of Science ®Google Scholar
• PACKER M: Proposal for a new clinical end point to evaluate the efficacy of drugs and devices in the treatment of chronic heart failure. I Cardiac Failure (2001) 7:176–182.
   PubMed Web of Science ®Google Scholar
• ABRAHAM WT, FISHER WG, SMITH AL et al.: Cardiac resynchronization in chronic heart failure. N. Engl. J. Med. (2002) 346:1845–1853.
   PubMed Web of Science ®Google Scholar